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Arterial reconstruction with use of autogenous
saphenous vein has proved an effective treatment of
atherosclerotic occlusive disease involving both the
coronary and the peripheral circulation. But the long-
term patency of these arterial bypasses is limited by
the process of intimal hyperplasia, which leads to
stenosis and eventual occlusion of 20% to 30% of
reconstructions.1,2 Vascular smooth muscle cell
(SMC) proliferation, migration, and extracellular
matrix protein production are three key cellular events
that contribute to the formation of intimal plaque.3,4
Arterial injury or the process of vein arterialization
that occurs when an autogenous vein is placed in the
arterial circulation results in the release of numerous
growth factors, cytokines, contractile agents, and
matrix proteins—all which have the potential to regu-
late cellular behavior within the vessel wall.
The mechanism by which these various factors
influence SMC behavior is through cellular receptors.
Growth factor receptors such as those for platelet-
derived growth factor (PDGF), fibroblast growth fac-
tor (FGF), epidermal growth factor (EGF), and trans-
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Purpose: Growth factors and cytokines such as platelet-derived growth factor (PDGF),
epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and transform-
ing growth factor beta (TGF-β) stimulate smooth muscle cell (SMC) proliferation and
extracellular matrix (ECM) protein production by binding and activating their respec-
tive receptors. Recent investigations suggest that simultaneous activation of integrins,
which are heterodimeric receptors for ECM, may also be required for growth factor and
cytokine function. In this study, we tested the hypothesis that activation of two inte-
grins, αvβ3 and α2β1, both previously identified in vascular SMCs, is necessary for
growth factor– and cytokine-induced vascular SMC dysfunction.
Methods: DNA synthesis was measured after stimulation of SMCs derived from human
saphenous vein with the growth factors PDGF-BB, EGF, and bFGF. SMC fibronectin
(Fn) production was measured (by means of Western blotting) in SMCs stimulated for
72 hours with TGF-β1 or EGF. Both endpoints were measured in the presence and
absence of antibodies that block the function of the αvβ3 and α2β1 integrins as well as
the α2 and β1 subunits.
Results: The αvβ3 integrin blocking antibody significantly inhibited PDGF-BB-, EGF-,
and bFGF-induced SMC proliferation. The αvβ3 integrin antibody also markedly inhib-
ited TGF-1- and EGF-induced SMC Fn production. Neither the α2β1 integrin nor the
α2 or the β1 subunits inhibited either proliferation or matrix protein production in
response to any of these agonists. 
Conclusion: The αvβ3 integrin is required for growth factor– and cytokine–induced SMC
proliferation and FN production, whereas α2β1 is not. Since activation of αvβ3 is
required for the activity of at least four distinct growth factors and cytokines, inhibition
of this integrin might be used as a therapeutic tool for the prevention of intimal hyper-
plasia. (J Vasc Surg 2000;31:375-81.)
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forming growth factor beta (TGF-β) have been well
defined, and their role in the events that lead to the
development of intimal hyperplasia has been studied
in some detail. However, the importance of a second
group of receptors found on SMCs, integrin recep-
tors, is less clear. Integrins are heterodimeric mem-
brane glycoproteins, composed of alpha and beta sub-
units. Thus far, 15 alpha and 8 beta subunits and
more than 22 integrin combinations have been iden-
tified.4-7 Both the alpha and the beta subunits are
transmembrane proteins containing large extracellular
domains, a single membrane-spanning region, and a
short cytoplasmic tail. Although integrin receptors
serve as sites for cellular attachment, these proteins
also mediate information transfer into cells. Integrins
serve as receptors for matrix proteins, and the effects
of extracellular matrix on cellular function are mediat-
ed through the attachment of matrix proteins to the
amino terminal extracellular domain of integrins, fol-
lowed by activation of intracellular signaling pathways
through the cytoplasmic carboxyl terminus.4,5 We and
others have localized a variety of integrin receptors on
vascular SMCs.8-12 The integrins identified thus far
are primarily from the β1 or β3 families; the most
prevalent appear to be αvβ3 and α2β1.8,12-16
In previous studies we have defined a role for
integrin receptors in matrix protein–induced SMC
migration and proliferation.11,17 Matrix proteins
have a potent stimulatory effect on SMC migration;
this effect appears to be mediated primarily through
the α2 and the β1 subunits11; αvβ3 and α5 are not
necessary for matrix protein–induced chemotaxis. In
saphenous vein SMCs, only the matrix protein colla-
gen I appears to have a stimulatory effect on SMC
proliferation.17 This effect is also mediated by α2β1,
rather than by αvβ3. From these studies, α2β1
appears to be the predominant functional integrin
that mediates SMC pathophysiology in response to
matrix proteins.
Some recent data suggest that integrin receptors
mediate not only the effects of matrix proteins but
also those of growth factors such as PDGF, FGF,
EGF, and TGF-β.18-22 We have previously observed
that PDGF-BB–induced chemotaxis is at least in
part inhibited by an antibody to the αvβ3 receptor.
Moreover, we and others have observed that inter-
actions between matrix protein/integrin receptors
and growth factors/their receptors can lead to syn-
ergistic enhancement of SMC migration and prolif-
eration.11,17-20
To further evaluate in SMCs the role of integrin
receptors in growth factor signaling, we chose two
growth factor–mediated events, proliferation and
fibronectin production. Using blocking antibodies,
we evaluated whether the integrins αvβ3 or α2β1
were necessary for SMC proliferation in response to
the potent mitogens PDGF-BB, bFGF, and EGF.
We also evaluated whether these integrins were nec-
essary for fibronectin production in response to
TGF-β and EGF (two signaling molecules that we
have previously found to be potent agonists of
fibronectin.)23 Our findings suggest that the inte-
grin αvβ3, but not α2β1, is required for growth fac-
tor– and cytokine–mediated events.
MATERIALS AND METHODS
General materials. Human recombinant
PDGF-BB, EGF, and bFGF were obtained from
Upstate Biotechnologies, Inc (Lake Placid, NY).
TGF-β1 was obtained from R & D Systems
(Minneapolis, Minn). Ethylenediaminetetraacetic
acid (EDTA), phenylmethylsulfonyl fluoride
(PMSF), sodium dodecyl sulfate (SDS), Nonidet-
P40, and Triton X-100 were from Sigma Chemical
Co (St Louis, Mo). Dulbecco’s Modified Eagle’s
Medium low glucose (DMEM), phosphate-
buffered saline (PBS), fetal bovine serum (FBS),
trypsin-EDTA, penicillin/streptomycin/ampho-
tericin B solution, L-glutamine, and N-2-
Hydroxyethylpiperazine-N’-2-ethanesulfonic acid
(HEPES) were from Gibco BRL (Gaithersberg,
Md). The protein assay kit was from Bio-RAD
(Hercules, Calif). The enhanced chemilumines-
cence (ECL) system was from Amersham Life
Science Inc (Little Chalfont, UK). Mouse mono-
clonal anti-human fibronectin antibody was
obtained from Calbiochem (San Diego, Calif).
Integrin antibodies. Mouse antihuman inte-
grin α2 (clone P1E6) and β1 (clone P4C10) mono-
clonal antibodies were purchased from Gibco BRL.
Mouse antihuman integrin αvβ3 (clone LM609)
and α2β1 (clone BHA2.1) monoclonal antibodies
were purchased from Chemicon International Inc
(Temecula, Calif). All four antibodies have been
demonstrated by their manufacturers to produce a
greater than 80% inhibitory effect at the dilutions
used in these experiments (1:100). Moreover, all
four antibodies have been previously found at this
laboratory, and at others, to inhibit various cellular
functions.11,16,24-27
Cell culture. Human SMCs were harvested from
explants of the remnant portions of saphenous vein
intended for aortocoronary or peripheral arterial
bypass grafting.28 The use of human saphenous vein
in these studies has been approved by the Institutional
Review Board at Weill/Cornell Medical College.
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Briefly, sections of saphenous vein were opened
lengthwise, and the endothelial and adventitial layers
were gently removed. Fragments of the medial layer
were placed onto polystyrene tissue culture plates and
outward-growing SMCs were harvested and subcul-
tured. Cells were maintained at 37°C and 5% CO2 in
DMEM supplemented with 10% FBS, 25-mmol/L
HEPES, 40-U/mL penicillin G, 40-µg/mL strepto-
mycin, 100-ng/ml amphotericin B, and 4.8-mM L-
glutamine. Cells in passages 2-5 were used for all
experiments. SMC identity was verified by immunos-
taining with anti-human α-actin antibody, and by a
characteristic “hill and valley” growth pattern.
Proliferation assay. Proliferation was assayed by
evaluating DNA synthesis. Confluent SMCs in 100-
mm dishes were detached with 0.05% trypsin/EDTA,
seeded onto 24-well polystyrene plates (10,000
cells/well) in 10% FBS-DMEM and allowed to attach
overnight. SMCs were starved in serum-free DMEM
for 72 hours and then stimulated for 24 hours with
the agonists as indicated. During the final 4 hours of
each assay, 2 µCi of [methyl 3H]-thymidine was
added to each well. At 24 hours, samples were pre-
cipitated with 10% trichloroacetic acid and the
radioactivity of incorporated 3H-thymidine in the
TCA-insoluble fraction was determined by using a
liquid scintillation counter. In the assays with blocking
integrin antibodies, quiescent SMCs were preincubat-
ed with 10 µg/mL of mouse monoclonal integrin
antibody or nonspecific mouse immunoglobulin G
(control) for 1 hour before stimulating with the
growth factors and cytokine agonists, PDGF (5
ng/mL), FGF (20 ng/mL), and EGF (20 ng/mL).
These concentrations have been shown previously to
produce maximal proliferation of human saphenous
vein SMCs.29 Proliferation experiments were per-
formed in triplicate and repeated three times with cell
cultures derived from the saphenous veins of three
different patients. 
Fibronectin assay. SMCs were seeded onto T-
60 polystyrene plates and allowed to grow to con-
fluence in media supplemented with 10% serum.
Cells were starved for 24 hours in serum-free media
and then incubated for 72 hours with EGF (100
ng/mL), TGF-β (10 ng/mL) or the vehicle control
in the presence or absence of blocking antibodies.
Fibronectin in the cell media was measured as
the following: 500-mL samples removed from the
cell media were diluted 1:2 in DMEM and cen-
trifuged at 1600 rpm for 6 minutes. Total protein
concentrations in the resulting supernatant were
measured by a modification of the method of Lowry
and protein amounts for the samples were equalized.
These samples were then diluted 1:2 in Laemmli
sample buffer, boiled at 100°C for 10 minutes, and
then subjected to SDS–polyacrylamide gel elec-
trophoresis (PAGE), with equal protein amounts
loaded into each of the lanes. The electrophoretical-
ly separated proteins were transferred to a polyvinyli-
dene difluoride (PVDF) membrane and after block-
ing, incubated with a primary antibody specific for
Fn (specific for the 220 Kda subunit) followed by a
horseradish peroxidase–conjugated secondary anti-
body. Labeled proteins were visualized with an ECL
system. Blots were quantified by using densitometry
(Eagle Eye II; Stratagene, La Jolla, Calif). Results
are expressed as percent increase above control.
Fibronectin experiments were repeated three times
with cell cultures derived from the saphenous veins
of three different patients.
Statistical analysis. All values are provided as
mean ± SD. Significance of results was determined with
Statview software (BrainPower, Inc, Calabasas, Calif)
on a Apple Macintosh system (Apple Computers,
Cupertino, Calif). Comparisons between blocking
antibody–treated groups and IgG controls were per-
formed by using a paired Student t test, and P < .05
was considered to indicate a significant difference.
RESULTS
DNA synthesis. To investigate the role of inte-
grins in SMC proliferation, quiescent SMCs derived
from human saphenous vein were stimulated for 24
hours with the growth factors PDGF-BB (5 ng/mL),
EGF (20 ng/mL), and bFGF (20 ng/mL) following
1 hour of preincubation with blocking antibodies to
αvβ3, α2β1, α2 and β1, and control IgG. All four
antibodies chosen for these studies have previously
been shown to inhibit their respective integrin recep-
tor or subunit.16,24-27 The inhibitory antibody to
αvβ3, at a dilution of 1:100, significantly inhibited
PDGF-BB-, EGF-, and bFGF-induced DNA synthesis
by 42% ± 12%, 81% ± 6%, and 74% ± 7%, respectively
(P < .05 for all comparisons). In contrast, antibodies to
α2β1, α2, and β1 at the same dilution had no effect
on DNA synthesis in response to any of the growth
factors tested (Figs 1-3). Thus, activation of the αvβ3
integrin is necessary for DNA synthesis in response to
PDGF-BB, EGF, and bFGF. However, activation of
the α2β1 integrin and the α2 and β1 subunits is not
necessary for DNA synthesis in response to these same
three mitogens.
Fibronectin production. To investigate the
role of integrins in extracellular matrix protein pro-
duction by SMCs, we chose the ubiquitous protein
fibronectin, which is found in intimal plaque after
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vascular injury. In previous studies, we had identified
both TGF-β (10 ng/mL) and EGF (100 ng/mL) to
be potent agonists of fibronectin production in
SMCs derived from human saphenous vein.23
Quiescent SMCs were stimulated for 72 hours with
both agonists at the same concentrations after 1
hour preincubation with blocking antibodies to
αvβ3, α2β1, α2 and β1, and control IgG. The
inhibitory antibody to αvβ3, at a dilution of 1:100,
inhibited TGF-β, and EGF stimulated fibronectin
production by 57% ± 19% (n = 3) and 65% ± 13%,
respectively (P < .05 for all comparisons; Fig 4). At
the same dilution, antibodies to α2β1, α2 and β1
had no significant effect on fibronectin production
in response to any of the growth factors tested.
Thus, activation of the αvβ3 integrin is necessary for
fibronectin production in response to TGF-β and
EGF. However, activation of the α2β1 integrin and
the α2 and β1 subunits is not necessary for
fibronectin production in response to either of these
agonists of extracellular matrix.
DISCUSSION
Many of the cellular events that lead to the devel-
opment of intimal hyperplasia may be dependent on
the function of integrin receptors. After arterial injury,
SMCs are stimulated by a multitude of factors, includ-
ing growth factors, cytokines, contractile agents, and
extracellular matrix proteins. Although integrins act as
sites of cellular attachment, these proteins can also
function as cellular receptors potentially mediating the
effects of some or all of these external stimuli.
Integrins were initially thought to act exclusively as
receptors for extracellular matrix proteins; however,
recent studies from ours and other laboratories
demonstrate an additional role for integrins in mediat-
ing the actions of growth factors and cytokines.11,18-22
In these experiments, we evaluated the role of
two integrin receptors, α2β1 and αvβ3, in growth
factor–mediated SMC proliferation and cytokine-
induced production of the extracellular matrix pro-
tein fibronectin. We chose to study these two inte-
grins because of their prevalence in SMCs derived
from human saphenous vein and because they are
representative of the two major beta subunits found
in vascular SMCs.8,11-16 Incubation of SMCs with
an inhibitory antibody to the αvβ3 integrin consis-
tently diminished SMC proliferation in response to
three known agonists of SMC growth, PDGF, FGF,
and EGF. This inhibition was marked and ranged
from 48% for PDGF to 74% for the growth factor
FGF. Moreover, the same antibody to αvβ3 dimin-
ished the stimulatory effect of TGF-β and EGF on
fibronectin production. Surprisingly, blocking anti-
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Fig 1. Effect of inhibitory integrin antibodies on SMC
DNA synthesis induced by PDGF-BB. DNA synthesis (24
hours) as measured by 3H-thymidine incorporation follow-
ing stimulation of quiescent vascular SMCs with PDGF-BB
(5 ng/mL) in the presence of antibodies to αvβ3, α2β1,
α2, β1, and IgG control (dilutions 1:100). Results are
expressed as percent of IgG control ± SD. Experiments
were performed in triplicate and repeated three times with
use of separate cell cultures. Data from a representative
example are shown (*P <.05 compared with control).
Fig 2. Effect of inhibitory integrin antibodies on SMC
DNA synthesis induced by EGF. DNA synthesis (24
hours) as measured by 3H-thymidine incorporation fol-
lowing stimulation of quiescent vascular SMCs with EGF
(20 ng/mL) in the presense of antibodies to αvβ3, α2β1,
α2, β1, and IgG control (dilutions 1:100). Results are
expressed as percent of IgG control ± SD. Experiments
were performed in triplicate and repeated three times with
use of separate cell cultures. Data from a representative
example are shown (*P <.05 compared with control).
bodies to the α2 and β1 subunits, as well as the
α2β1 integrin, had no effect on either SMC prolif-
eration or fibronectin production.
We as well as other investigators have previously
demonstrated a role for integrin receptors in growth
factor–induced cellular events. Inhibition of αvβ3
with the same antibody used in these experiments
(LM609) diminished SMC chemotaxis in response
to PDGF-BB by approximately 50%.11 Moreover, a
blocking antibody to αvβ3 has been shown to inhib-
it SMC migration in response to insulin-like growth
factor-1.30 Using the c7E3 antibody (Reopro) that
binds the β3 integrin, Stouffer et al19 found inhibi-
tion of SMC proliferation in response to α-throm-
bin, despite the fact that α-thrombin has its own
receptor distinct from that of αvβ3. Although we
had found that a blocking antibody to αvβ3 inhibit-
ed PDGF-induced SMC proliferation, the c7E3
antibody did not inhibit SMC proliferation in
response to PDGF AB or BB. The discrepancy
between our findings and those of Stouffer et al may
be related to our use of a different antibody,
LM609, which is specific for αvβ3 (whereas c7E3 is
directed against the αllbβ3 receptor on platelets
with cross-reactivity to αvβ3) or the use of a differ-
ent cell type (human saphenous vein SMCs were
used in our experiments, whereas human aortic
SMC were used in the studies by Stouffer et al). In
any event, prior studies and our current data provide
substantial support for the hypothesis that integrin
receptors are necessary, at least in part, for mediating
the actions of both growth factors and cytokines. 
Further evidence of an interaction between
growth factor and integrin receptors can be derived
from experiments where matrix proteins and growth
factors combine to produce synergistic effects. We
have previously shown that PDGF and collagen type
l synergistically enhance SMC proliferation, an effect
that appears to be related to activity of the α2β1
integrin.17 Pickering et al15 have shown that FGF
alone is a weak stimulant of SMC migration, where-
as FGF is a potent stimulant of chemotaxis when
SMCs are placed on collagen-coated membranes, an
effect also related to the α2β1 integrin. In both of
these circumstances, growth factor and integrin
receptors in some manner interact to allow this syn-
ergistic response to occur. 
Interestingly, in the experiments reported in this
article the αvβ3 integrin is necessary for growth factor
and cytokine function in the absence of simultaneous
stimulation of SMCs with a matrix protein. For these
experiments, SMCs were cultured on plastic dishes not
coated by extracellular matrix proteins, and serum-free
conditions were used during the period of stimulation.
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Fig 3. Effect of inhibitory integrin antibodies on SMC
DNA synthesis induced by bFGF. DNA synthesis (24
hours) as measured by 3H-thymidine incorporation fol-
lowing stimulation of quiescent vascular SMCs with bFGF
(20 ng/mL) in the presense of antibodies to αvβ3, α2β1,
α2, β1, and IgG control (dilutions 1:100). Results are
expressed as percent of IgG control ± SD. Experiments
were performed in triplicate and repeated three times with
use of separate cell cultures. Data from a representative
example are shown (*P <.05 compared with control).
Fig 4. Effect of inhibitory integrin antibodies on SMC
fibronectin production induced by TGF-β and EGF.
Fibronectin production as measured by Western blotting
following 72 hours stimulation of quiescent vascular
SMCs with TGF-β (20 ng/mL) (upper panel) and EGF
(100 ng/mL) (lower panel) in the presence of antibodies
to αvβ3, α2β1, α2, β1, and IgG control (dilutions 1:100).
Fn was assayed in the cell medium with use of an antibody
specific for the 220-kDa subunit. All experiments were
repeated three times with cells from three separate cul-
tures. Data from a representative example are shown.
The only external stimulus to which SMCs were
exposed was the growth factor or cytokine under
study; matrix proteins were not present in the experi-
mental environment (although SMCs during the
course of these studies may have produced some
endogenous extracellular matrix). The finding that
integrin receptors are necessary for the isolated action
of growth factors or cytokines is somewhat surprising.
Several explanations for the synergistic interaction
of growth factor and integrin receptors have been
postulated. One possible mechanism is that growth
factors promote the expression of new integrin recep-
tors. Alternatively, growth factors may activate exist-
ing receptors. Basson et al31 found that TGF-β
increased the expression of αvβ3 in vascular SMCs.
Interestingly, TGF-β did not alter the expression of
α2β1. Janat et al32 have demonstrated that PDGF-BB
can increase the expression of the β3 subunit, where-
as this same growth factor has no effect on expression
of the β1 subunit. Growth factor stimulation may also
enhance clustering of integrin receptors, an event that
leads to integrin receptor activation.21,22,33 Activated
integrin receptors may, in turn, directly stimulate cel-
lular functions such as proliferation by acting through
their own signaling pathways. Thus, growth factors,
by activating their own receptors and also by simulta-
neously activating integrins, can provide a dual stimu-
lus for cellular function.
There are substantial data demonstrating a role for
αvβ3 in SMC proliferation. This effect is mediated by
αvβ3 through a series of signaling pathways that have
been incompletely defined. Integrin receptors includ-
ing αvβ3 initially promote clustering of a number of
intracellular signaling proteins, including focal adhe-
sion kinase, tenacin, and Src at sites termed focal
adhesions. These clustered proteins, in turn, activate
mitogen-activated protein kinase, phospholipase C,
and phosphoinositol-3-kinase—all of which are
known mediators of cellular proliferation.34-41 A rela-
tionship between αvβ3 and fibronectin production
has not been previously described. However, from the
findings reported in this article, we postulate that
stimulation of vascular SMC with PDGF, FGF, EGF,
and TGF-β leads to increased production and activa-
tion of αvβ3. In turn, αvβ3 enhances the effect of
these growth factors on SMC proliferation, migra-
tion, and extracellular matrix protein production. 
The prevalence of both αvβ3 and α2β1 in the
artery or vein wall after vascular injury has not been
well defined. αvβ3 has been identified in atheroscle-
rotic plaque derived from coronary arteries in
patients undergoing heart transplantation.14 αvβ3
was found within the intima as well as throughout
the neointimal and medial layers of these vessels. In a
balloon injury model in which the brachial artery of
baboons was used, αvβ3 was not identified in the
uninjured artery but was found at the luminal surface
and in the neointima of vessels 1 week after injury.19
Although these findings suggest an association
between αvβ3 and atherosclerosis and intimal hyper-
plasia, a careful temporal evaluation of the neointimal
accumulation of αvβ3 after vascular injury has not yet
been performed. The α2β1 integrin has been identi-
fied in normal arteries. In immunohistochemical
studies performed 6 weeks after a balloon injury to
the saphenous arteries of baboons, α2β1 was found
to be diminished in the newly developed neointi-
ma.18 Moreover, in cultured baboon SMCs, an anti-
body that activates the β1 subunit diminished both
migration and proliferation of baboon vascular
SMCs. These studies would suggest that, unlike
αvβ3, α2β1 either has little importance in the forma-
tion of intimal hyperplasia or that this integrin might
even negatively regulate the hyperplastic process.
Our current studies, which reveal a significant role
for αvβ3 and no role for α2β1 in growth factor and
cytokine–stimulated SMC function, support the
above findings, and emphasize the potential impor-
tance of αvβ3 as an integral factor in the events that
follow arterial injury.
The αvβ3 integrin appears to be an important
mediator—not only for the pathophysiologic effects
of matrix proteins on vascular SMCs but also for
those related to growth factors and cytokines. This
integrin may be a prime target for therapies designed
to prevent the neointimal process that so often com-
plicates vascular reconstructions.
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